<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-12T16:38:06Z</responseDate>
  <request identifier="oai:figshare.com:article/34034689" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34034689</identifier>
        <datestamp>2026-09-30T17:26:56Z</datestamp>
        <setSpec>category_4</setSpec>
        <setSpec>category_12</setSpec>
        <setSpec>category_13</setSpec>
        <setSpec>category_14</setSpec>
        <setSpec>category_15</setSpec>
        <setSpec>category_873</setSpec>
        <setSpec>category_734</setSpec>
        <setSpec>category_64</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_1</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;Effects of AZP2006 in aged mice infused with α-syn PFF preparation in the SNpc, treated for 5 weeks.&lt;/p&gt;</dc:title>
          <dc:creator>Noelle Callizot (5660677)</dc:creator>
          <dc:creator>Georgia Culley (15148575)</dc:creator>
          <dc:creator>Grace Flower (25145065)</dc:creator>
          <dc:creator>Laura Rouvière (16400955)</dc:creator>
          <dc:creator>Véronique De Conto (25145068)</dc:creator>
          <dc:creator>Alexandre Wojcinski (6340172)</dc:creator>
          <dc:creator>Catherine Botto (25145071)</dc:creator>
          <dc:creator>Cecilia Estrella (1618609)</dc:creator>
          <dc:creator>Alexandre Henriques (359791)</dc:creator>
          <dc:creator>Philippe Verwaerde (1618624)</dc:creator>
          <dc:subject>Biochemistry</dc:subject>
          <dc:subject>Cell Biology</dc:subject>
          <dc:subject>Genetics</dc:subject>
          <dc:subject>Molecular Biology</dc:subject>
          <dc:subject>Neuroscience</dc:subject>
          <dc:subject>Chemical Sciences not elsewhere classified</dc:subject>
          <dc:subject>Biological Sciences not elsewhere classified</dc:subject>
          <dc:subject>Cancer</dc:subject>
          <dc:subject>promising therapeutic approach</dc:subject>
          <dc:subject>lewy bodies ).</dc:subject>
          <dc:subject>several lysosomal enzymes</dc:subject>
          <dc:subject>restoring lysosomal homeostasis</dc:subject>
          <dc:subject>lysosomal availability depend</dc:subject>
          <dc:subject>like models (&lt;</dc:subject>
          <dc:subject>parkinson &amp;# 8217</dc:subject>
          <dc:subject>maintaining lysosomal function</dc:subject>
          <dc:subject>div &gt;&lt; p</dc:subject>
          <dc:subject>neuroprotective effects involve</dc:subject>
          <dc:subject>several parkinson ’</dc:subject>
          <dc:subject>lysosomal function</dc:subject>
          <dc:subject>neuroprotective effects</dc:subject>
          <dc:subject>lysosomal system</dc:subject>
          <dc:subject>lysosomal dysfunction</dc:subject>
          <dc:subject>parkinson ’</dc:subject>
          <dc:subject>neuroprotective action</dc:subject>
          <dc:subject>disease models</dc:subject>
          <dc:subject>vivo &lt;/</dc:subject>
          <dc:subject>vitro &lt;/</dc:subject>
          <dc:subject>ultimately supporting</dc:subject>
          <dc:subject>prone proteins</dc:subject>
          <dc:subject>pathohistological hallmarks</dc:subject>
          <dc:subject>mitochondrial injury</dc:subject>
          <dc:subject>genetic connections</dc:subject>
          <dc:subject>endoplasmic reticulum</dc:subject>
          <dc:subject>dopaminergic neurons</dc:subject>
          <dc:subject>direct link</dc:subject>
          <dc:subject>clinical development</dc:subject>
          <dc:description>&lt;p&gt;Body mass evolution during 35 days of daily treatment with vehicle or AZP2006 post-lesion (A). Representative IHC images TH (red)/α-syn (green)/Iba1 (purple) (B). IHC analysis shows the total number of TH(+) neurons (C), area of α-syn accumulation in TH(+) neurons (D) and the number of Iba1(+) microglia in the SNpc (E) expressed as % of sham. Raw values for sham (i.e., 100%); TH(+) neurons = 65 ± 1.6; α-syn area/TH(+) neuron = 168 ± 9.4 µm&lt;sup&gt;2&lt;/sup&gt;; Iba1(+) cells = 53 ± 2.8. Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. &lt;sup&gt;##&lt;/sup&gt;p &lt; 0.01 or &lt;sup&gt;####&lt;/sup&gt;p &lt; 0.0001 from sham; **p &lt; 0.01; ***p &lt; 0.001 and ****p &lt; 0.0001 from α-syn+vehicle injury, (n = 7 mice / group).&lt;/p&gt;</dc:description>
          <dc:date>2026-09-30T17:26:42Z</dc:date>
          <dc:type>Image</dc:type>
          <dc:type>Figure</dc:type>
          <dc:identifier>10.1371/journal.pone.0359269.g005</dc:identifier>
          <dc:relation>https://figshare.com/articles/figure/_p_Effects_of_AZP2006_in_aged_mice_infused_with_-syn_PFF_preparation_in_the_SNpc_treated_for_5_weeks_p_/34034689</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
